Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zirconium-89-labeled messenger RNA lipid nanoparticles
- Development stage
- Unknown
- Lead developer
- Okayama University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Zirconium-89-labeled messenger RNA lipid nanoparticles (89Zr-labeled mRNA-LNPs) are radiolabeled nanoparticles developed by Okayama University and the University of Tokyo as a positron emission tomography (PET) imaging probe. Designed as a non-invasive tool for the in vivo pharmacokinetic and biodistribution evaluation of mRNA-based therapeutics, these nanoparticles are formulated with a lipid mixture (including ALC-0315, DSPC, cholesterol, ALC-0159, and DSPE-PEG(2000)-Azide) encapsulating EGFP mRNA. The nanoparticles are radiolabeled with zirconium-89 (89Zr) via click chemistry using a DFO-DBCO chelator. This diagnostic agent enables real-time, quantitative visualization of mRNA-LNP migration from the injection site to target tissues such as the lymph nodes, liver, and spleen, facilitating the preclinical optimization and clinical translation of mRNA delivery systems.
- Other names
- 89Zr-labeled mRNA-LNPs89Zr-labeled messenger RNA lipid nanoparticleszirconium-89-labeled mRNA-LNPszirconium89-labeled mRNA-LNPszirconium 89-labeled mRNA-LNPs
Beyond the preview
Go deeper on zirconium-89-labeled messenger RNA lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zirconium-89-labeled messenger RNA lipid nanoparticles.